Many low abundance noncoding antisense RNAs, which are transcribed on the opposite strands of genomic loci, endogenously suppress corresponding sense gene expression; inhibition or removal of antisense transcript leads to locus-specific upregulation of sense mRNA, protein and function.
Many low abundance noncoding antisense RNAs, which are transcribed on the opposite strands of genomic loci, endogenously suppress corresponding sense gene expression; inhibition or removal of antisense transcript leads to locus-specific upregulation of sense mRNA, protein and function.
Supplementary Methods:
Mouse studies: We obtained approval for mouse studies from the Institutional Animal Care and Use Committee at The Scripps Research Institute, where the animal experiments were performed. We used 10 eight-week-old male C57BL/6 mice for in vivo experiments. We prepared mice with chronic indwelling cannulae in the dorsal third ventricle implanted subcutaneously with osmotic mini-pumps that delivered continuous infusions (0.11 microliter/h) of synthetic antisense oligonucleotide directed against Bdnf-AS (mBdnf-AntagoNAT9) or control oligonucleotide (inert sequence that does not exist in human or mouse) at a dose of 1.5 mg/kg/d for 4 weeks. We connected tubing to the exit port of the osmotic minipump and tunneled it subcutaneously to the indwelling cannula, such that the treatments were delivered directly into the brain. At 5 d post-implantation all animals received daily intra-peritoneal (IP) injection of BrdU (80 mg/kg), for five consecutive days. At the 28 th day post-surgery, we sacrificed the animals and excised three tissues (hippocampus, frontal cortex and cerebellum) from each mouse brain for quantitative RNA measurements. RNA extraction is described in the Supplementary Methods.
Design of modified AntagoNAT molecules:
We designed and tested a number of DNA based Supplementary Fig. 12 ). Sequences of various AntagoNATs, as well as all other siRNAs, primers and probes used for these studies are listed in supplementary table-1.
Rapid Amplification of cDNA Ends (RACE): Sequence information for the potential mouse
Bdnf-AS was retrieved from the UCSC Genome Bioinformatics web site. Using RACE ready cDNA (Ambion catalog number 3200-3209) from the mouse brain we amplified the 5' and 3' ends of Bdnf-AS by nested PCR with gene specific and kit primers. Alternatively, using 250 ng poly "A" RNA from the testis as starting materials and utilizing the PRLM RACE kit (Applied Biosystems catalog number AM1700), we generated 5' and 3' end libraries and performed PCR followed by sequencing to identify the mouse Bdnf-AS transcript. We excised the 3' and 5' PCR products of both mouse and human from an agarose gel and cloned them into the T-Easy vector (Promega catalog number TM042). We sequenced positive colonies from each series.
Real-Time PCR (RT-PCR):
We carried out RT-PCR with the GeneAmp 7900 machine (Applied Biosystems). cDNA synthesis reaction contained random hexamers, 200-400 ng of RNA, 2.5 mM mixture of dNTP, MgCl2, and appropriate buffer. The PCR reactions contained 20-40 ng cDNA, Universal Mastermix, 300 nM of forward and reverse primers, and 200 nM of probe in a final reaction volume of 15 µl. We designed the primer/probe set using FileBuilder software (Applied Biosystems). Primers were strand-specific for sense-antisense pairs and the probes covered exon boundaries to eliminate the chance of genomic DNA amplification. The PCR conditions for all genes were as follows: 50 ºC for 2 min then 95 ºC for 10 min then 40 We measured expression of Bdnf and Bdnf-AS in a panel of monkey brain RNA samples (n = 2) by RT-PCR using human primers and probe. The brain regions tested from the monkey samples were: 1) motor cortex 2) frontal cortex 3) hippocampus 4) amygdala 5) motor cortex 6) insula 7)
temporal cortex 8) interior partial cortex 19) striatum 10) cerebellum 11) striatum 12) septum 13) occipital cortex 14) pituitary gland. Both BDNF and BDNF-AS transcripts were expressed in many tissues and cell lines tested, and the expression levels of BDNF mRNA was between 10 to 100-fold greater than the BDNF-AS transcript.
RNA extraction and RT-PCR of the mouse brain samples:
We euthanized mice after 28 days and excised the brains. One hemibrain from each mouse was fixed in 4% formaldehyde overnight for histological studies. We excised another hemibrain for RNA quantitative measurement from the hippocampus, frontal cortex and cerebellum. We extracted RNA after homogenization in Trizol reagent (Invitrogen, 15596-026) according to the manufacturer's protocol. We separated the aqueous phase and added an equal volume of 70% ethanol before passing the samples through Qiagen RNeasy columns (QIAGEN, 74106) and we subjected those RNA samples to on-column DNAse treatment for removal of DNA contamination. We used 400 ng of each sample for the first strand cDNA synthesis and carried out RT-PCR measurements as described above. We plotted the percentile changes in RNA levels, for individual tissues as compared to control mice, in each graph.
Cell culture and transfection:
We purchased human cortical neurons, HCN-1A, originating from the brain of an 18-month old female from ATCC (ATCC # CRL-10442). These cells were reported to be positive for a number of neuronal markers including neurofilament protein, neuron specific enolase (NSE) and gamma aminobutyric acid (GABA). We cultured cells in a DMEM medium supplemented with 10% FBS. We purchased human glial cells (M059K) that originated from the brain of a 33 year-old male with malignant glioblastoma, from ATCC (ATCC # CRL-2365). We cultured these cells in a mixture of DMEM and F12 plus 10% FBS, 1% NEAA, 2.5 mM L-glutamate, 15 mM HEPES, 0.5 mM sodium pyruvate, and 1% sodium bicarbonate. We We designed 14 functional and two inert control oligonucleotides (that do not have targets in the mammalian genome). Cells were incubated for various time points before RNA extraction, using Qiagen RNeasy columns.
Statistical analysis:
We performed all experiments with 6-20 biological and 3-6 technical repeats. The data presented in the graphs is a comparison with control-treated groups after posthoc analysis of the corresponding treatment factor using main effects in a two-way analysis of variance (ANOVA). We calculated the significance of each treatment as a p-value. As depicted in each graph, (p < 0.05) was considered significant.
Western blot:
We transfected HEK293T cells with 10 nM of BDNF-AS, or control siRNA. We disrupted cells, 48 h post transfection, with 200 µl of Laemmli sample buffer (Biorad) containing 350 mM DTT. We separated 20 µl of the lysate on a 10% SDS PAGE and transferred it to a nitrocellulose membrane overnight. Then we incubated the membrane with primary antibody for MecP2 (Abcam), BDNF (Promega, catalog number G164B) and secondary antibody conjugated to HRP. After addition of HRP substrate, we detected the chemiluminescent signal with X-ray film. We stripped the same membrane and reused it for detection of β-Actin as a loading control.
ELISA:
We transfected cells with 20 nM of BDNF-AS siRNA or control siRNA. The cell supernatant was collected for ELISA experiments. Alternatively, we extracted total protein from mouse brain tissues embedded in protein extraction buffer plus protease inhibitors (BCA kit, Fisher) and homogenized with the bioruptor and metal beads. Total protein was measured using BCA protein assay kit (Pierce catalog number 23227) and sample loads were normalized to total protein concentrations. We purchased the ELISA kits for human BDNF from Promega (catalog number G7611) or mouse Bdnf Millipore (catalog number CYT306) and we performed ELISA following the supplier's protocol. We subtracted average absorbance of three repeats at 450 nm from background and normalized it to the control sample. Samples containing serial dilutions of cloned BDNF and BDNF-AS cDNA were used to draw individual standard curves for each transcript. Both sense and antisense transcripts are expressed in the brain and muscular tissues. BDNF mRNA levels are generally 10-100 folds higher than that of the BDNF-AS transcript, except for in testis, kidney and heart, which contain equal or higher levels of BDNF-AS. BDNF mRNA levels are low in post-natal tissues, except for in the brain, heart, cervix and ovary. BDNF-AS transcript levels are high in the kidney, testis, ovary and brain.
Dissecting mouse hippocampal neural stem cells in neurospheres:

Supplementary Figure 2: Expression of BDNF and BDNF-AS in embryonic tissues:
We observed high expression levels of BDNF and BDNF-AS transcripts in the 12-week embryo.
Thus, we sought to determine the pattern of expression of both transcripts in human embryonic tissues. We bought a panel of RNA samples from various human embryonic tissues (Applied Biosystems). We assessed the expression of BDNF and BDNF-AS transcripts by RT-PCR, normalizing each transcript to the expression of the whole embryo. We found that BDNF-AS transcript levels are high in most of the embryonic tissues examined, with notably high levels in embryonic muscle and lung tissues.
Supplementary Figure 3: Ratio of BDNF-AS to BDNF in human tissues:
We performed RT-PCR and assessed the expression levels of BDNF and BDNF-AS transcripts in each tissue. Next, we normalized the expression of BDNF-AS to that of BDNF in the same tissue. We found that the BDNF-AS to BDNF ratio is vastly different amongst various tissues.
The BDNF-AS to BDNF ratio is low in the brain, 12-week embryo, bladder and heart. This ratio is high (up between 2-to 16-fold) in the kidney, liver, thymus, thyroid, adipose tissue, esophagus, cervix, small intestine, ovary, and trachea. The BDNF-AS to BDNF ratio is equal to or less than 50% different in the colon, lungs, placenta, prostate, skeletal muscle, spleen and testis.
Supplementary Figure 4: Expression of Bdnf and Bdnf-AS in the monkey brain:
We determined the expression levels of Bdnf and Bdnf-AS transcripts in RNA samples from Rhesus monkey brain tissues (n=2), by RT-PCR. We used human primer/probe sets that contain one nucleotide mismatch to the Rhesus monkey genome. We found that both transcripts are expressed in various brain tissues; however, endogenous levels of Bdnf-AS are much lower than Knockdown of BDNF-AS, using siRNAs-1 (10 nM) targeting the non-overlapping region of the BDNF-AS transcript, caused a 6-fold upregulation of BDNF (sense) mRNA (****= P < 0.0001).
Results depicted here were obtained from experiments in HEK293T cells, using beta actin (left panel) or 18S rRNA (right panel) as endogenous controls and the mock transfection as a reference sample. This experiment is intended to show that choice of endogenous controls or reference calibrator sample does not change the observed upregulation of BDNF mRNA.
Supplementary Figure 8: Controls for real-time PCR reactions:
To ensure the validity of the RT-PCR, we included several controls. We included a no reverse transcriptase enzyme reaction (NRC) in all RT-PCR plates to make sure that there was no genomic DNA contamination. We also ran final RT-PCR products on a gel to ensure that only one product exists per reaction/probe. After completion of RT-PCR, final products from the BDNF, BDNF-AS and beta-actin probes, as well as corresponding no template controls (NTC)
were separated on a 1.2% agarose gel and stained with ethidium bromide. There was only one band detectable in each lane, suggesting that RT-PCR probes were amplifying the correct product. The BDNF-AS transcript contains a 225-nucleotide overlapping region that has full complementarity to the BDNF mRNA. Our hypothesis is that RNA-RNA interactions may be responsible for the discordant regulation of BDNF by its antisense transcript. To determine the regulatory role of BDNF-AS on BDNF mRNA, we utilized gapmers (AntagoNATs) containing both LNA and 2'OMe RNA modification to block the interaction between sense and antisense transcripts. We covered overlapping region by tiling hBDNF-AatagoNATs. We found that the use of hBDNF-AntagoNATs upregulates the BDNF mRNA. We observed marginal downregulation of BDNF-AS transcript, which was not expected for 2'OMe-RNA containing blocking oligos. We tested 16 hBDNF-AntagoNATs (14-mers each with the sequences provided below) and found that blocking the first half of the BDNF-AS overlapping region has a greater effect on the upregulation of BDNF mRNA. Specifically, hBDNF-AntagoNAT1 and hBDNFAntagoNAT4 caused significant upregulation of BDNF mRNA. repressive chromatin mark at the BDNF genomic locus (main text figure 6 ). These data suggest that the BDNF-AS transcript might directly impact H3K27 trimethylation.
Supplementary
Method: HEK293T cells were treated with control or BDNF-AS siRNA followed by ChIP analysis using antibodies against H3K4Met3, H3K36Met3, H3K27Met3 or H3K9Met3 chromatin marks. Immunoprecipitation was followed by RT-PCR of the extracted DNA, using 16 primer sets that covered the entire BDNF locus as indicated in the schematic above. The observed chromatin modification did not extend toward neighboring genes. These results suggest antisense-mediated chromatin modification, which is unlike H3K27met3 not extended to the promoter region.
Our findings show that the repressive or active chromatin marks can be induced or modified by ncRNA expression. We assessed the expression of immediate neighboring genes and found that removal of BDNF-AS does not affect their expression, suggesting that the antisense RNA-mediated regulation of gene expression is a highly specific event. Considering the low abundance and high potency of BDNF-AS, we believe that antisense RNA-mediated regulation of BDNF occurs at the nuclear and transcriptional levels. Local accumulation of antisense RNA or formation of sense-antisense RNA duplexes, which can be processed to small RNA intermediates, trigger the cascade of events that result in modification of chromatin structure and the activation or deactivation of BDNF transcription. We find that the removal of BDNF-AS causes a reduction in suppressive H3K27met3 chromatin marks over the promoter and body of the BDNF gene locus. This modification is local and is expanded only to the promoter of the BDNF transcript. Identification of the components and the cascade of events that result in antisense RNA-mediated modification of chromatin structure are currently being investigated.
